This is an expert consensus document, not a clinical trial. It was produced by a multidisciplinary Chinese panel — spanning otolaryngology, audiology, vestibular medicine, public health, and basic science — under the newly formed China Consortium for Refractory Inner Ear Diseases. No patient sample size applies; this is a guidelines document, not a study with enrolled participants.
The consensus defines refractory inner ear disease (RIED) as conditions affecting the cochlea and vestibule that persist despite following standard treatment protocols. The clinical picture typically involves some combination of hearing loss, tinnitus, and vertigo. The document covers epidemiology, proposed mechanisms, diagnostic criteria, differential diagnosis, and long-term management strategies.
The consensus acknowledges that RIED incidence appears to be rising based on recent domestic and international epidemiological data, and that the condition affects not only hearing and balance but also mental health and social participation.
Key limitations: this document reflects Chinese clinical practice and expert opinion rather than new trial data. The recommendations are intended to standardize care within China’s healthcare system and may not map directly to clinical protocols in other countries. As a consensus rather than a systematic review with graded evidence, the strength of individual recommendations will vary, and external validation has not yet been reported.
What This Means for You
If your tinnitus has not improved after following standard treatments, and you also experience vertigo or fluctuating hearing, RIED may be a relevant category to discuss with your specialist. This consensus does not introduce new treatments, but it does provide a structured framework for diagnosis and management that your clinician may find useful — particularly if your case spans hearing, balance, and tinnitus symptoms together.